Huajian Medical has seen its market value increase by HK$14 billion over two months, reaching HK$17 billion. This surge follows the company's strategic moves in the digital real-world assets (RWA) sector, including the completion of the Nanjing ETHK Building, the world's first R&D base for RWAs. Since July, Huajian Medical has acquired a controlling stake in Guofu Quantum and launched an innovative drug intellectual property tokenization fund. The company, now renamed Huajian Digital Industry Group, is collaborating with Renhe Pharmaceutical to establish an OTC drug RWA exchange in the United States. This initiative aims to advance the digitization and on-chain circulation of medical assets, marking a significant step in the integration of blockchain technology within the pharmaceutical industry.